BioSpace News Archive

Amarin Corporation plc issued the following statement in response to Sarissa’s latest misstatements regarding the Company’s management compensation:

Veracyte, Inc. announced that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.

Alcon, the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2022.

Apellis Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares.

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2022.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China.

Everest Medicines held a ceremony to celebrate the initiation of operations and successfully carrying out trial production runs at its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang Province.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant with neovascular age-related macular degeneration (nAMD) has been successfully dosed in the phase 1 clinical trial of IBI333, a recombinant anti-VEGF–A and anti-VEGF-C bispecific fusion protein.

Alvotech announced that it will release financial results for full year 2022, after U.S. markets close on Wednesday, March 1, 2023.

GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders.